Brain Tissue

This page includes Agent-based three-dimensional cancer-tumour-microenvironment (TME) models developed within the scope of the TÜBİTAK 1001 Project with the number 120S987.

The models were developed by using scRNA data from healthy brain tissue and glioblastoma, cell type specific metabolic models and mechanistic information on cell-cell interactions from literature, see the HIBIT24 poster on overview of the project.

The models had few tumour cells at the initial time, the tumour growth and treatment under given conditions were simulated for about 45 days. Videos of the simulations are given below:

Oxygen availability (low, medium, high)

Below videos show the effect of oxygen levels on the tissue, oxygen both effects the metabolism and also signalling between the cells (HIF is released under hypoxia). Higher oxygen levels lead to faster growth.

Oxygen Level – Low

Oxygen Level – Mid

Oxygen Level- High

Glucose availability (low, medium, high)

Glucose availability effects the biomass production rate, cell divide when they are able to accumulate enough biomass. Also lactate is produced by cell types that are capable of producing lactate, which is turn used by cell types which can metabololise lactate. Metabolic behaviour of the cell is calculated via FBA based on their metabolic models.

Glucose Level – Low

Glucose Level – Mid

Glucose Level – High

Cell division rate (low, mediım high as a proxy of effects of mutations on regulation of cell division)

Cell division takes place when accumulated biomass passes a threshold, this threshold is used as a proxy for deregulation of cell division by mutated cell cycle check inhibitors. Cells divide faster if they are mutated.

Brain – Max Biomass 3e-4

Brain – Max Biomass 6e-4

Brain – Max Biomass 15e-4

Cell mobility

Migration Speed – 2.5

Migration Speed – 5

Migration Speed – 10

CAR-T therapy (small, medium, large number of CAR-T cell administration)

Cart Dose cn – 375

Cart Dose cn -750

Cart Dose cn – 1500

CAR-T therapy (under low-medium-high glucose conditions)

Brain – cart_optxglucose Low

Brain – cart_optxglucose Mid

Brain – cart_optxglucose High

ICI therapy (administration of ICI agent at early- advanced-very late stages of tumor progression)

Ici Initial Time – 7

Ici Initial Time – 15

Ici Initial Time – 30

ICI therapy (weekly, bi-weekly, monthly administration of ICI agent)

Ici Period – 7

Ici Period – 14

Ici Period – 28

Initial number of CAR-T cells (dose effect)

Brain – crat_init_thres 250

Brain – crat_init_thres 500

Brain – crat_init_thres 750

ICI therapy (under low-medium-high glucose conditions)

Brain – cartopxglucose_var High

Brain – cartopxglucose_var Mid

Brain – cartopxglucose_var Low

Brain – No Cancer

Brain – ici_optxglucose_var – High

Brain – ici_optxglucose_var – Mid

Brain – ici_optxglucose_var – Low

Brain – cart_optxglucose_var – High

Brain – cart_optxglucose_var – Mid

Brain – cart_optxglucose_var – Low